EP Patent

EP2792746A1 — Oligonucleotide and therapeutic agent for hyperlipidemia containing same as active ingredient

Assigned to National Cerebral and Cardiovascular Center · Expires 2014-10-22 · 12y expired

What this patent protects

The oligonucleotide of the present invention includes a sugar-modified nucleoside, the sugar-modified nucleoside has a cross-linked structure between 4'-position and 2'-position, and the oligonucleotide is capable of binding to the apolipoprotein C-III gene. According to the pres…

USPTO Abstract

The oligonucleotide of the present invention includes a sugar-modified nucleoside, the sugar-modified nucleoside has a cross-linked structure between 4'-position and 2'-position, and the oligonucleotide is capable of binding to the apolipoprotein C-III gene. According to the present invention, an oligonucleotide useful as a therapeutic agent for hyperlipidemia that is excellent in binding affinity to the apolipoprotein C-III gene, stability and safety is provided.

Drugs covered by this patent

Patent Metadata

Patent number
EP2792746A1
Jurisdiction
EP
Classification
—
Expires
2014-10-22
Drug substance claim
No
Drug product claim
No
Assignee
National Cerebral and Cardiovascular Center
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.